Preview Mode Links will not work in preview mode

Sep 28, 2023

Featuring an interview with Dr Paul G Richardson, including the following topics:

  • Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
  • Similarities and differences between iberdomide, mezigdomide and standard...


Sep 28, 2023

Featuring a slide presentation and related discussion from Dr Paul G Richardson, including the following topics:

  • Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
  • Published efficacy and safety findings...


Sep 22, 2023

Featuring perspectives from Dr Nicole Lamanna and Dr William G Wierda, including the following topics:

  • Introduction: Mentoring Fellows (0:00)
  • Case: A woman in her mid 50s with multiple cardiovascular comorbidities and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) receives bendamustine/rituximab induction...


Sep 14, 2023

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 2: Key Data Sets with Bispecific Antibodies in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes — Martin Hutchings, MD, PhD

CME information and...


Sep 14, 2023

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 1: Role of Bispecific Antibody Therapy in Follicular Lymphoma — Loretta J Nastoupil, MD

CME information and select...